Nataliya P. Buxbaum, M.D.
Dr. Buxbaum is a bone marrow transplant (BMT) physician-scientist studying immune-mediated barriers to successful BMT. Dr. Buxbaum’s laboratory and clinical investigations are centered on chronic graft-versus-host disease (cGVHD), which occurs when the immune cells of the donor recognize the organs of the recipient as foreign with resultant damage to these tissues. A significant number of BMT patients are affected by cGVHD and new and effective treatments for this disease are needed. Dr. Buxbaum’s research efforts are focused on understanding the biology of cGVHD through the use of pre-clinical models and evaluating pediatric patients on the Natural History of cGVHD study at the NCI.
Dr. Buxbaum is elucidating the biology of immunologic events that underlie chronic graft-versus-host disease (cGVHD). T cells are central to cGVHD pathophysiology. Through the use of stable water isotope labeling Dr. Buxbaum gained insight into differential in vivo behavior of key T cell subsets in the pre-clinical cGVHD model. Dr. Buxbaum is now exploiting these biological differences to develop novel clinical imaging methods for cGVHD. Furthermore, Dr. Buxbaum is working on identifying new therapeutic targets and treatments for cGVHD in the pre-clinical model that will be translated into clinical studies for patients affected by cGVHD.
- Biol Blood Marrow Transplant. 24: 1415-1423, 2018. [ Journal Article ]
In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host disease.JCI Insight. 2: 2017. [ Journal Article ]
Comparing DNA enrichment of proliferating cells following administration of different stable isotopes of heavy water.Scientific Reports. 7: 4043, 2017. [ Journal Article ]
Chronic GVHD in Children.In: Graft Versus Host Disease: Living With The After Effects of Bone Marrow/Stem Cell Transplant. nbmtLINK 49-56, 2015. [ Book Chapter ]
Sensitive GC-MS/MS Method to Measure Deuterium Labeled Deoxyadenosine in DNA from Limited Mouse Cell Populations.Anal Chem. 85(9): 4613-20, 2013. [ Journal Article ]
Dr. Buxbaum first came to the NIH as a Howard Hughes Medical Institute (HHMI) research scholar in 2002. She graduated from Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ in 2005 and completed her residency in Pediatrics at Columbia Presbyterian, Children’s Hospital of New York in 2008. She then trained in Pediatric Hematology-Oncology through the Johns Hopkins and National Cancer Institute (NCI) combined fellowship. Dr. Buxbaum is board certified in Pediatrics (2009) and Pediatric Hematology Oncology (2013) and currently serves as an Assistant Clinical Investigator in the Experimental Transplantation and Immunology Branch, NCI.
|Julian Assmann Ph.D.||Postdoctoral Fellow (Visiting)|
|Donald E. Farthing Ph.D.||Biochemist (Contr.)|